Phathom Pharmaceuticals, Inc. PHAT Accrued Interest On Revenue Interest Financing Liability Net Of Payments
Accrued Interest On Revenue Interest Financing Liability Net Of Payments at other companies
Other financials
Where this comes from
Reported directly by Phathom Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept phat:AccruedInterestOnRevenueInterestFinancingLiabilityNetOfPayments.
The official record: Phathom Pharmaceuticals, Inc.’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Phathom Pharmaceuticals, Inc.'s accrued interest on revenue interest financing liability net of payments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Phathom Pharmaceuticals, Inc.'s accrued interest on revenue interest financing liability net of payments?
- Phathom Pharmaceuticals, Inc. (PHAT) reported accrued interest on revenue interest financing liability net of payments of $3.54M in Q1 2026.
- How has Phathom Pharmaceuticals, Inc.'s accrued interest on revenue interest financing liability net of payments changed year-over-year?
- Phathom Pharmaceuticals, Inc.'s accrued interest on revenue interest financing liability net of payments decreased by 55.9% year-over-year, from $8.04M to $3.54M.
- What does accrued interest on revenue interest financing liability net of payments mean?
- This represents the non-cash accrual of interest expenses related to revenue-based financing arrangements, net of any actual cash payments made during the period. It reflects the cost of capital for financing structures where repayment is tied to future product revenue streams. Monitoring this helps investors understand the ongoing debt service burden and the impact of non-dilutive financing on future cash flows.